Trial Profile
A MULTICENTER PHASE II STUDY TO EVALUATE ACTIVITY AND TOLERABILITY OF CISPLATIN (CDDP) AND FOTEMUSTINE (FTM) COMBINATION IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH BRAIN METASTASES.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jun 2011
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Fotemustine (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2011 New trial record